Bioclinica’s Image Redact AI tool enables trials to edit sensitive information from videos, photos and PDFs to ensure compliance and safeguard patient data
While the change signifies the life-sciences solutions firm’s commitment to help customers and patients, day-to-day functions will remain much the same.
Conducted by SubjectWell, the survey of patients with Type 2 diabetes reveals how ethnicity and other factors play a part in trial participation tendencies.
A leader from Oracle Health Sciences examines the dynamic, challenging year and highlights creativity and ingenuity displayed by research professionals.
A representative from the global CRO outlines how forces like COVID-19, decentralized studies, globalization and others are driving change in the industry.
The two organizations will collaborate on development of synthetic arms for clinical studies, drawing from millions of patient records and trial subject.
Conducted via a partnership between Parexel and CISCRP, the study reveals insights about the needs and concerns of pediatric patients and their families.
The Medical Data Platform, an RPM solution from VivaLNK, handles clinical trials, cardiac monitoring, remote and in-patient monitoring and other tasks.
The head of the CRO’s Global Center of Excellence for Decentralized Clinical Trial Strategy outlines key developments in 2020, and keys to success in 2021.
The newly formed group seeks to bring together research professionals to accelerate adoption and introduce industry standards in virtual and hybrid trials
The clinical trial tech firm has enhanced its electronic patient-reported outcome module, and landed an investment to help promote various technologies.
Through organizations like the Association of Clinical Research Organizations, clinical research professionals are helping decentralized research evolve.
A real-world evidence generation expert discusses how clinical trial teams can make use of RWE to help improve diversity and inclusivity in their studies.
A leader from data-centric CRO Quanticate shares perspective on how the pandemic has disrupted trials, and what tools and technologies can keep work going.
Taking place December 9, the Digital Advances in Clinical Trials webinar covers notable advances in clinical trial technology, and the future of the field.
The division of the National Institutes of Health has begun enrolling hospitalized patients in a trial investigating various potential COVID-19 treatments.
Intelligent Tissue Group has launched its Intelligent Clinical trials facility to help assess the effectiveness and safety of potential new treatments.
The pharma giant and the clinical-stage drug developer will join on a pilot study investigating a candidate’s potential in overcoming resistance of a cancer drug.
A leader from the global CRO shares an update on their new Accellacare clinical research network, and perspective on the importance of patient centricity.
RedHill Biopharma has completed enrollment for its Phase II study exploring the use of opaganib in treating COVID-19 patients that have severe pneumonia.
According to one New Yorker, encountering the AI-assisted TrialJectory technology helped cut through the uncertainty to provide information and solutions.
The precision medicine firm is joining with the oncology network in an effort to help improve treatment options and outcomes for cancer patients worldwide.
An expert from the global pharmaceutical firm shares how working with other organizations and putting patients at the center can benefit clinical research.
During a free editorial webinar on December 9, a panel of clinical trial experts will offer a range of insights into the future of research technology.
A leader from the global CRO talks about how use of RWE in clinical trials can benefit research sites and sponsors, and satisfy regulatory requirements.
The company’s annual survey of pharmaceutical and biotechnology leaders reveals their needs, plans and concerns for the immediate and long-term future.
The clear evidence of increased risk of COVID-19 infection amongst ethnic minority groups, people from Black and Asian backgrounds, is of urgent public health importance, according to the authors of a paper published today by The Lancet.
Preliminary results from a recent clinical trial indicate the drug touted by US leaders as a possible treatment offers no significant benefit to patients.
The two companies are working together to develop AT-527, an orally administered, direct-acting antiviral therapy for patients diagnosed with COVID-19.
